Denali Therapeutics Inc. Common Stock (DNLI)
Stock · NASDAQ · Health Care
$17.61as of 10/16/2026
Price chart
Active signals
DNLI Signal Track Record
How signals performed across all stocks →What DNLI's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -0.8% | 50% | October 6, 2026 |
| Bollinger Band Breakout | 24 | 0.0% | 50% | June 15, 2026 |
| Bollinger Band Breakdown | 18 | +1.6% | 56% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 17 | -6.4% | 24% | September 28, 2026 |
| Any 20-session window (baseline) | -0.6% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (S…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 503
- Website
- www.denalitherapeutics.com
Fundamentals
- 1-day range
- $18.01$18.53
- Market cap
- $3.92B
- P/E (trailing)
- —
- P/E (forward)
- -7.59
- EPS (trailing)
- $-2.84
- Dividend yield
- —
- Beta
- 1.06
- Avg. volume
- 1.55M
How Denali Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2023 annual results
Source: 10-K filed Feb 28, 2024 · via SEC EDGAR / Finnhub
Forecasts
16 analyst ratings
Denali Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- DNLIDenali Therapeutics Inc. Common Stock$17.61▼ 3.98%Market cap $3.92BP/E —$13.75$27.3
- RLAYRelay Therapeutics Inc. Common Stock$16.28▼ 5.90%Market cap $3.78BP/E —$5.95$21.27
- ADPTAdaptive Biotechnologies Corporation Common Stock$24.02▼ 6.10%Market cap $3.77BP/E —$12$30.74
- CRSPCRISPR Therapeutics AG Common Shares$49.25▼ 4.41%Market cap $4.99BP/E —$44.12$75.06
- KODKodiak Sciences Inc Common Stock$85.75▼ 2.69%Market cap $2.84BP/E —$10.94$104
- BEAMBeam Therapeutics Inc. Common Stock$23.47▼ 5.10%Market cap $2.81BP/E —$20.23$38.26
- TARSTarsus Pharmaceuticals Inc. Common Stock$68.07▼ 4.11%Market cap $2.81BP/E —$53.89$91.53
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DNLI Denali Therapeutics Inc. Common Stock | $3.92B | — | $17.61 | ▼ 3.98% | $13.75$27.3 |
| RLAY Relay Therapeutics Inc. Common Stock | $3.78B | — | $16.28 | ▼ 5.90% | $5.95$21.27 |
| ADPT Adaptive Biotechnologies Corporation Common Stock | $3.77B | — | $24.02 | ▼ 6.10% | $12$30.74 |
| CRSP CRISPR Therapeutics AG Common Shares | $4.99B | — | $49.25 | ▼ 4.41% | $44.12$75.06 |
| KOD Kodiak Sciences Inc Common Stock | $2.84B | — | $85.75 | ▼ 2.69% | $10.94$104 |
| BEAM Beam Therapeutics Inc. Common Stock | $2.81B | — | $23.47 | ▼ 5.10% | $20.23$38.26 |
| TARS Tarsus Pharmaceuticals Inc. Common Stock | $2.81B | — | $68.07 | ▼ 4.11% | $53.89$91.53 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Denali Therapeutics Q2 2026 Earnings Call Transcriptbenzinga · 10/12/2026
- Denali Therapeutics Inc. (DNLI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/14/2026
Insider Activity
Insider Actions →- Chin Peter Scott · September 4, 2026 · Sale1.7K @ $22.29
- Nancy Thornberry · September 2, 2026 · Sale615 @ $23.74
- Nancy Thornberry · September 2, 2026 · Sale10.8K @ $22.85
- Schuth Alexander O. · September 1, 2026 · Sale2.8K @ $23.44
- Watts Ryan J. · August 12, 2026 · Gift32.2K
- Schuth Alexander O. · August 11, 2026 · Sale2.9K @ $25.07
- Jennifer E. Cook · June 3, 2026 · Grant6.4K
- Steve E. Krognes · June 3, 2026 · Grant19.2K
- Steve E. Krognes · June 3, 2026 · Grant6.4K
- Klein Peter S · June 3, 2026 · Grant19.2K
- Klein Peter S · June 3, 2026 · Grant6.4K
- Jay T. Flatley · June 3, 2026 · Grant19.2K
- Jay T. Flatley · June 3, 2026 · Grant6.4K
- BAKER JULIAN · June 3, 2026 · Grant19.2K
- BAKER JULIAN · June 3, 2026 · Grant6.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 140.66M
- Total value held
- $2.47B
- Institutional holders
- 263
- Unknown13.03M
- Unknown12.07M
- Unknown8.52M
- Unknown7.01M
- Unknown6.27M
- Unknown6.15M
- Unknown4.58M
- Unknown4.43M
- Unknown4.41M
- Unknown3.73M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Denali Therapeutics Shares Test Fair Value Amid Pullback
Denali Therapeutics shares have pulled back, testing the $19.37 support level. The 14‑day RSI sits at 30, indicating a possible oversold condition, while the support_reject signal suggests the level may hold. Analysts average a target of $36.06, with a range of $27 to $42, well above the current price and the 52‑week low of $13.75. The pullback could be seen as a chance to assess fair value.
Denali Therapeutics Shares Test Fair Value Amid Pullback. Denali Therapeutics shares have pulled back, testing the $19.37 support level. The 14‑day RSI sits at 30, indicating a possible oversold condition, while the support_reject signal suggests the level may hold. Analysts average a target of $36.06, with a range of $27 to $42, well above the current price and the 52‑week low of $13.75. The pullback could be seen as a chance to assess fair value.